-
1Academic Journal
المؤلفون: K. E. Roshchina, A. H. Bekyashev, D. R. Naskhletashvili, E. A. Moskvina, I. K. Osinov, A. N. Savvateev, D. A. Khalafyan
المصدر: Опухоли головы и шеи, Vol 12, Iss 3, Pp 95-101 (2022)
مصطلحات موضوعية: renal cancer, brain metastases, overall survival, prognostic factors, local recurrence, distant metastases, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
2Academic Journal
المؤلفون: A. V. Santimov, R. A. Rupp, I. G. Alekseev, N. N. Plutova, E. A. Moskvina, M. K. Kruchina, A. N. Tarasenko, N. E. Sokolova, E. A. Savelyeva, I. Yu. Bogdanov, D. V. Ivanov, T. I. Kandrina, O. V. Kopanevich, A. Ya. Grafskaya, N. A. Ignatyeva, D. B. Pulukchu, N. V. Pavlova, I. V. Solodkova, O. V. Kalashnikova, T. L. Kornishina, M. F. Dubko, V. G. Chasnyk, M. M. Kostik
المصدر: Современная ревматология, Vol 11, Iss 3, Pp 26-32 (2017)
مصطلحات موضوعية: kawasaki disease, diagnosis, treatment., Medicine
وصف الملف: electronic resource
-
3Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev
المصدر: Опухоли головы и шеи, Vol 6, Iss 4, Pp 30-34 (2017)
مصطلحات موضوعية: vemurafenib, melanoma, brain metastases, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
4Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, V. B. Karakhan, E. A. Moskvina, E. V. Prozorenko
المصدر: Опухоли головы и шеи, Vol 0, Iss 4, Pp 19-25 (2015)
مصطلحات موضوعية: kidney cancer, brain metastases, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
5Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, E. A. Moskvina
المصدر: Опухоли головы и шеи, Vol 0, Iss 4, Pp 17-21 (2015)
مصطلحات موضوعية: breast cancer, brain metastases, chemotherapy, drug therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
6Academic Journal
المؤلفون: E. A. Moskvina, V. A. Gorbunova, D. R. Naskhletashvili, A. Kh. Bekyashev, S. V. Medvedev, S. B. Peterson
المصدر: Опухоли головы и шеи, Vol 0, Iss 3, Pp 59-62 (2015)
مصطلحات موضوعية: brain metastases, breast cancer, capecitabine, radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
7Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, M. B. Bychkov, A. Kh. Bekyashev, V. B. Karakhan, V. A. Aleshin, D. M. Belov, E. A. Moskvina
المصدر: Опухоли головы и шеи, Vol 0, Iss 3, Pp 56-58 (2015)
مصطلحات موضوعية: glioblastomas, recurrence, bevacizumab, irinotecan, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
8Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, M. B. Bychkov, A. Kh. Bekyashev, V. B. Karakhan, V. A. Aleshin, D. M. Belov, E. A. Moskvina
المصدر: Опухоли головы и шеи, Vol 0, Iss 3, Pp 63-65 (2015)
مصطلحات موضوعية: brain, metastases, gefitinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
9Academic Journal
المؤلفون: D. R. Naskhletashvili, A. Kh. Bekyashev, V. A. Aleshin, D. M. Belov, E. A. Moskvina, E. G. Chmutin
المصدر: Опухоли женской репродуктивной системы, Vol 0, Iss 2, Pp 28-29 (2014)
مصطلحات موضوعية: brain, metastases, breast cancer, chemotherapy, Gynecology and obstetrics, RG1-991
وصف الملف: electronic resource
-
10
المصدر: Ural Medical Journal. 20:85-89
مصطلحات موضوعية: Forensic science, Service (business), Tuberculosis, medicine, Medical emergency, Business, medicine.disease, The Republic
-
11
المؤلفون: A. H. Bekyashev, V A Aleshin, V. B. Karakhan, D. R. Naskhletashvili, A. A. Pogosova, E. V. Prozorenko, K. E. Roshchina, M. B. Bychkov, D. M. Belov, E. A. Moskvina, Vera Gorbunova, T. G. Gasparyan, A. A. Mitrofanov
المصدر: Russian Journal of Oncology. 25:146-153
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, General Medicine, Brain damage, Treatment results, medicine.disease, Systemic therapy, Targeted therapy, Metastasis, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, Molecular targets, Medicine, medicine.symptom, business
-
12
المؤلفون: V. V. Pivdiablyk, E. Yu. Moskvina, V. V. Piven
المصدر: Oil and Gas Studies. :100-109
مصطلحات موضوعية: business.product_category, Drilling rig, Computer science, Continuous monitoring, Wire rope, 02 engineering and technology, engineering.material, 010502 geochemistry & geophysics, Residual, 01 natural sciences, Fatigue limit, GeneralLiterature_MISCELLANEOUS, Pulley, Resource (project management), 020401 chemical engineering, Physics::Space Physics, engineering, Astrophysics::Solar and Stellar Astrophysics, 0204 chemical engineering, business, ComputingMethodologies_COMPUTERGRAPHICS, 0105 earth and related environmental sciences, Marine engineering, Rope
-
13Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, A. H. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev, Д. Р. Насхлеташвили, В. А. Горбунова, А. Х. Бекяшев, Л. В. Демидов, Г. Ю. Харкевич, С. М. Банов, И. В. Самойленко, К. А. Барышников, К. В. Орлова, И. А. Утяшев, Н. В. Петенко, И. Г. Маркина, Е. А. Москвина, С. В. Медведев
المصدر: Malignant tumours; № 4s1 (2016); 67-73 ; Злокачественные опухоли; № 4s1 (2016); 67-73 ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: лучевая терапия, таргетная терапия
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/290/260; Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.; Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012; 32: 4655-4662.; Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487-496.; Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295-1304.; Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for theRev 2006;3: CD003869.; Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-3650.; D'Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014; 6: 101-114.; Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.; Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139.; Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010; 12: 1193–1199.; Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor – mutant non-small cell lung cancer. Lung Cancer. 2016; 93: 59–68.; Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013; 82: 282–287.; Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never- smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65: 351–354.; Naskhletashvili D. R., Gorbounova V. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in the treatment of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). 37th ESMO Congress, Austria, Vienna, 28 September – 02 October 2012, abstract 1330.; Насхлеташвили Д. Р., Горбунова В. А., Бычков М. Б., Бекяшев А. Х., Карахан В. Б., Алешин В. А., Белов Д. М., Москвина Е. А. Гефитиниб («Иресса») в лечении метастазов немелкоклеточного рака легкого в головном мозге. Опухоли головы и шеи, № 3, 2012 год, стр. 63–65.; Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of their reversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015; 10: 156–163.; Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4: 1046–1061.; Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR- mutated non-small-cell lung cancer. N Engl J Med. 2015; 372: 1700–1709.; Sakagami H, Konagai S, Yamamoto H, et al. ASP8273, a novel mutantselective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. Cancer Res. 2014; 74 (suppl; abstr 1728).; Lee KO, Cha MY, Kim M, et al. Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor. Cancer Res. 2014;74 (suppl; abstr LB-100).; Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015; 58: 8200–8215.; Bohn JP, Pall G, Stockhammer G, et al. Targeted therapies for the treatment of brain metastases in solid tumors. Target Oncol. Epub 2016 Jan 29.; Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALKS-rearranged non-small- cell lung cancer and brain metastases. J Clin Oncol. 2015; 33: 1881–1888.; Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small- cell lung cancer and brain metastasis. J Clin Oncol. 2016; 34: 123–129.; Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29: e443-e445.; Shaw AT, Kim DW, Mehra R, et al. Ceritinibin ALK-rearranged non-small cell lung cancer. New Engl J Med. 2014; 370: 1189–1197.; Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013; 14: 590–598.; Shaw A, Mehra R, Tan DSW, et al. BM-32 Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trial. Neuro Oncol. 2014; 16: v39.; Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014; 74: 1023–1028.; Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib resistant ALK-rearranged non- small-cell lung cancer (AF-002JG): results from the dose- finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15: 1119–1128.; Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2015; 33 (suppl; abstr 8062).; Kerstein D, Gettinger S, Gold K, et al. LBA4: evaluation of anaplastic lymphoma kinase (ALK) inhibitor brigatinib [AP26113] in patients with ALK+ non-small cell lung cancer (NSCLC) and brain metastases. Ann Oncol. 2015; 26: i60-i61.; Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor- negative breast cancer. Cancer. 2012; 118: 4652–4659.; Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcome sin patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113: 2638–2645.; Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from regist HER. Clin Cancer Res. 2011; 17: 4834–4843.; Olson EM, Abdel-Rasoul M, Maly J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013; 24: 1526–1533.; Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013; 14: 244–248.; Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006; 15: 219–225.; Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87: 586–592.; Tamura K, Kurihara H, Yonemori K, et al. 64Cu-DOTA- trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med.2013; 54: 1869–1875.; Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol. 2007; 85: 311–317.; Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66: 1630–1639.; Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy] phenyl-6-[5-([2-(methylsulfonyl) ethyl]aminomethyl)-2-furyl]- 4-quinazolinamine; GW572016). Drug Metab Dispos. 2009; 37: 439–442.; NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009; 15: 1452–1459.; Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabin ein patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14: 64–71.; Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А., Бекяшев А. Х., Карахан В. Б., Михина З. П., Медведев С. В. Лекарственная терапия больных раком молочной железы с метастатическим поражением головного мозга. Российское общество клинической онкологии, официальная газета общества, 2015 год, № 1, стр. 10–11.; Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и с метастатическим поражением головного мозга. Вопросы онкологии, № 3, 2013 год, том 59, стр. 347–351.; Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372: 724–734.; Bartsch R, Berghoff AS, Vogl U, et al. Activity of T-DM1 in Her2- positive breast cancer brain metastases. Clin Exp Metastasis. 2015; 32: 729–737.; Long GV, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book. 2013; 33: 393–398.; Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118: 4014–4023.; Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379: 1893–1901.; Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 1087–1095.; Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014; 50: 611–621.; Kefford R, Malo M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open label, single arm, phase 2, multicenter study. Paper presented at: 2013 Society for Melanoma Research Congress; November 2013; Philadelphia, PA.; Berghoff AS, Preusser M. The future of targeted therapies for brain metastases. Future Oncol. 2015; 11: 2315–2327.; Vyshak A. Venur, MD, and Manmeet S. Ahluwalia. Targeted Therapy in Brain Metastases: Ready for Primetime? 2016 ASCO EDUCATIONAL BOOK, e123-e130.; https://www.malignanttumors.org/jour/article/view/290; undefined
-
14Academic Journal
المؤلفون: D. R. Naskhletashvili, V. A. Gorbunova, E. A. Moskvina, A. Kh. Bekyashev, V. B. Karakhan, Z. P. Mikhina, S. V. Medvedev, Д. Р. Насхлеташвили, В. А. Горбунова, Е. А. Москвина, А. Х. Бекяшев, В. Б. Карахан, З. П. Михина, С. В. Медведев
المصدر: Malignant tumours; № 3 (2014); 116-120 ; Злокачественные опухоли; № 3 (2014); 116-120 ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: лекарственная терапия, brain metastases, drug therapy, метастазы в головном мозге
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/77/81; Насхлеташвили Д. Р. Автореферат по теме кандидатской диссертации: «Современные возможности консервативного лечения больных раком молочной железы и мелкоклеточным раком легкого с метастазами в головной мозг». 2002 год, 36 страниц.; Насхлеташвили Д. Р., Горбунова В.А, Бекяшев А. Х., Москвина Е. А. Таргетная терапия в комплексном лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и c метастатическим поражением головного мозга. Материалы мультидисциплинарного форума по лечению рака молочной железы, Санкт-Петербург, 24–25 октября 2013 года, абстракт, стр. 33.; Насхлеташвили Д. Р., Горбунова В. А., Москвина Е. А. Современные возможности таргетной терапии в лечении больных раком молочной железы с гиперэкспрессией Her-2/neu и с метастатическим поражением головного мозга. Вопросы онкологии, № 3, 2013 год, том 59, стр. 347–351.; Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972–2977, 2003 (иностранный источник).; Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002; 38: 487–496 (иностранный источник).; Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16:1772–1777 (иностранный источник).; Chang E., Lob S. Diagnosis and Management of Central Nervous System Metastases from Breast Cancer. The Oncologist 2003, Vol. 8, No. 5, 398–410 (иностранный источник).; Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 2005; 71: 61–65 (иностранный источник).; Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327–334 (иностранный источник).; De la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 76:11–17, 1984 (иностранный источник).; Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest 2006; 24: 466–468 (иностранный источник).; Franciosi V, Cocconi G, Michiara M et al., Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599–1605 (иностранный источник).; Gorbounova V. A., Bychkov M. B., Michina Z. P., Naskhletashvili D. R. Tеmozolomide in patients with brain metastases. 16th International Congress of Anti-Cancer Treatment (01–04/02/2005 г., Париж, Франция). Abstract book, стр. 306 (иностранный источник).; Heinrich B, Brudler O, Siekiera W, et al: Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 22:37, 2003 (abstr 147) (иностранный источник).; Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006; 15: 97–99 (иностранный источник).; Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295–1304 (иностранный источник).; Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608–3617 (иностранный источник).; Naskhletashvili D., Gorbounova V., Bychkov M., Bekyashev A., Karakhan V., Aleshin V., Moskvina E., Markovich A., Michina Z., Medvedev S. Targeted therapy (lapatinib and/or trastuzumab) and capecitabine in breast cancer (BC) patients with Her-2/neu overexpression and brain metastases (BM). EORTC-EANO-ESMO conference 2013 on trends in Central Nervous System Malignancies, Prague, 22–23 March 2013, abstract 164 (+ poster P.164) (иностранный источник).; Naskhletashvili D. R. Gorbunova V. A., Bychkov M. B., Chmutin G. E., Karahan V. B., Aloshin V. A., Moskvina E. A. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. Journal of Clinical Oncology 28:7s, 2010 (suppl; abstr 1125) (иностранный источник).; Naskhletashvili D. R. Gorbunova V., Bychkov M., Rzaev D., Chmutin G., Karahan V., Aloshin V., Michina Z., Alieva S., Moskvina E. The role of temozolomide for patients with metastatic brain disease. Abstracts from the 9th meeting of the Europion Association of Neuro-Oncology, Maastricht, the Netherlands, September 16–19, 2010, p. 57–58 (иностранный источник).; Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 2001; 24: 256–260 (иностранный источник).; Rosner D, Flower A, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993; 12: 508a (иностранный источник).; Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–839 (иностранный источник).; Samaan NA, Buzdar AU, Aldinger KA, et al: Estrogen receptor: A prognostic factor in breast cancer. Cancer 47:554–560, 1981 (иностранный источник).; Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003; 5: 833–834 (иностранный источник).; Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3: CD003869 (иностранный источник).; Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001;24:421–424 (иностранный источник).; Wardley AM, Danson S, Clayton AJ, et al: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 21:61a, 2002 (abstr 241) (иностранный источник).; Weitzen R, Zach L, Kaufman B, et al: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 21:316, 2002 (abstr 1936) (иностранный источник).; https://www.malignanttumors.org/jour/article/view/77
-
15
المؤلفون: E. A. Moskvina, V. B. Karakhan, A. Kh. Bekyashev, M. B. Bychkov, V. A. Aleshin, Vera Gorbunova, D. R. Naskhletashvili
المصدر: Russian Journal of Biotherapy. 17:22-30
مصطلحات موضوعية: Oncology, Nervous system, medicine.medical_specialty, business.industry, medicine.medical_treatment, Central nervous system, General Engineering, medicine.disease, Systemic therapy, Radiosurgery, Metastasis, Targeted therapy, medicine.anatomical_structure, Internal medicine, medicine, General Earth and Planetary Sciences, business, Lung cancer, General Environmental Science, EGFR inhibitors
-
16
المؤلفون: A. L. Shavkin, V. N. Luchaninova, E. A. Moskvina, A. Yu. Zvereva, M. K. Kruchina
المصدر: Pacific Medical Journal. :95-97
مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, Proteinuria, business.industry, Disease, medicine.disease, Hypoproteinemia, medicine, Etiology, Childbirth, In patient, medicine.symptom, business, Congenital nephrotic syndrome, Nephrotic syndrome
-
17Academic Journal
المؤلفون: D R Naskhletashvili, G E Chmutin, V B Karakhan, V A Aleshin, R G Fu, E A Moskvina, D M Belov, A B Luk'yanchenko, E A Ivanova
المصدر: Современная онкология, Vol 12, Iss 1, Pp 13-14 (2010)
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
-
18
المؤلفون: A. R. Abdrakhmanov, N V Morozyuk, M. I. Timerzyanov, E V Chugunova, P V Minaeva, E. N. Moskvina
المصدر: Sudebno-meditsinskaya ekspertiza. 64:8
مصطلحات موضوعية: medicine.medical_specialty, Medical education, General Medicine, Computer-assisted web interviewing, Forensic Medicine, Forensic science, Tatarstan, Workflow, Work (electrical), Surveys and Questionnaires, Epidemiology, medicine, Humans, Workplace, Psychology, Occupational Health
-
19
المؤلفون: E S, Philippova, I V, Bazhenov, L I, Volkova, E Y, Moskvina, E L, Turova, Y V, Popova
المصدر: Urologiia (Moscow, Russia : 1999). (6)
مصطلحات موضوعية: Surveys and Questionnaires, Quality of Life, Humans, Reproducibility of Results, Urinary Bladder, Neurogenic, Russia
-
20
المؤلفون: K. V. Syzrantseva, E. Yu. Moskvina
المصدر: MECHANICS, RESOURCE AND DIAGNOSTICS OF MATERIALS AND STRUCTURES (MRDMS-2019): Proceedings of the 13th International Conference on Mechanics, Resource and Diagnostics of Materials and Structures.
مصطلحات موضوعية: Vibration, Acoustics, Spectral analysis, Workover, Geology, Field conditions